LIVONIA, Mich., June 2, 2011 /PRNewswire/ -- Genentech and Novartis have the best image among oncologists and hematologists, according to Market Strategies International, a market research consultancy that recently completed its 2011 MSImage study. The study evaluated more than 30 sales force, corporate equity and R&D attributes to determine which measures drive a company's image and performance in this rapidly growing marketplace.
Amgen, Sanofi-aventis and Eli Lilly/ImClone round out the top five among oncologists, and Celgene, Millennium: The Takeda Oncology Company and Amgen round out the top five for hematologists.Rank
AmgenWhile Genentech maintains a slim lead across office-based and hospital-based oncologists and hematologists, Novartis remains the only other company tied with Genentech for top-tier status. And, although Genentech slightly extended their lead across several key measures, Novartis is now ranked first by hospital oncologists in the Sales Force dimension and closed the gap on Genentech in the Product/R&D dimension.
"Last year, Novartis joined Genentech as a top-tier company among office-based oncologists, but now the improvement is mixed. There are specific areas that Novartis needs to improve on if it hopes to claim the top spot from Genentech," said Brock Walter, vice president, Specialty Pharmaceuticals division, Market Strategies International.
Study results indicate that top performers engage in behaviors that are most important to physicians. Specifically, there is a strong correlation between a highly favorable image and behaviors such as a physician's likelihood to:
|SOURCE Market Strategies International|
Copyright©2010 PR Newswire.
All rights reserved